<DOC>
	<DOCNO>NCT01760083</DOCNO>
	<brief_summary>CTOs common among patient angina , detect around 20 % patient undergoing coronary angiography . Treatment CTO find constitute 7 % PCI practice average . One reason under-presentation CTOs PCI target lesion lack evidence-based medical data treatment indication , continue low level accept evidence treatment CTOs PCI PCI guideline . Patients CTO represent patient stable coronary artery disease . The COURAGE trial compare PCI optimal medical therapy stable coronary disease show difference mortality myocardial infarction two treatment option . However , CTOs include COURAGE trial . But trial confirm superiority PCI OMT control symptom angina , high cross-over rate PCI . Whether PCI CTO superior OMT reduce MACE patient large ischaemic burden never test randomize control trial . While compel evidence registry study clinical prognostic benefit follow successful PCI CTO compare PCI failure , randomize control trial contemporary PCI use drug-eluting stent versus optimal medical therapy . The COURAGE trial nuclear sub-study confirms prognosis closely related extent residual ischaemia PCI effective reduce residual ischaemia optimal medical therapy alone . This confirm earlier retrospective data suggest benefit PCI great patient moderate ( 10-20 % ) severe ( &gt; 20 % ) ischaemia . Study hypothesis : PCI Biolimus elute stent implantation plus OMT superior OMT alone improve health status 12-month follow-up , noninferior respect composite cause death/ non fatal MI 36-month follow , patient CTO epicardial coronary artery &gt; 2.5 mm diameter chronic stable angina evidence ischemia viability territory subtend CTO</brief_summary>
	<brief_title>A Randomized Multicentre Trial Evaluate Utilization Revascularization Optimal Medical Therapy Treatment Chronic Total Coronary Occlusions</brief_title>
	<detailed_description />
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<criteria>≥ 18 year age write informed consent CTO native coronary artery ) Stable angina , b ) myocardial ischaemia territory supply CTO , c ) viability akinetic myocardium ( &lt; 50 % transmural late enhancement MRI normal rest perfusion scan ) CTO locate segment 13 ( RCA ) , 67 ( LAD ) , 1112 ( LCx ) target artery ≥2.5mm AMI NSTEACS within 1 month Significant untreated coronary stenosis territory CTO Patients MVD significant nonCTO stenosis deem unsafe treat nonCTO lesion first ( e.g . Significant proximal LAD lesion chronically occlude RCA ) Patient unsuitable 12 month dual antiplatelet therapy Any exclusion criterion PCI DES Pregnant nursing patient plan pregnancy period 1 year follow index procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>